Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IL-12 Clear all
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

NCT00003439
View directory record Official record
Conditions
Cancer
Interventions
recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 13, 2026, 5:28 PM EDT
Completed No phase listed Observational Results available

Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions

NCT00026793
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection

NCT00001763
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

NCT00111605
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Not applicable Interventional

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

NCT00000896
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
3
States / cities
San Diego, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Cancer in the Abdomen

NCT00003046
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 13, 2026, 5:28 PM EDT
Not listed Phase 2 Interventional

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

NCT02542124
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sézary Syndrome
Interventions
NM-IL-12 and TSEBT
Biological
Lead sponsor
Neumedicines Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Stanford, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

NCT00028535
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Small Cell Lung Cancer
Interventions
trastuzumab, paclitaxel, recombinant interleukin-12
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 13, 2026, 5:28 PM EDT
Not listed Phase 2 Interventional

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

NCT03567720
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
tavokinogene telseplasmid, Pembrolizumab, Immunopulse, nab paclitaxel, gemcitabine plus carboplatin
Biological · Device · Drug
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 13, 2026, 5:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

NCT04327986
View directory record Official record
Conditions
Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
Interventions
M7824, M9241, SBRT
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Melanoma

NCT00003556
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

NCT02199496
View directory record Official record
Conditions
Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
Interventions
Stelara (ustekinumab)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

NCT02480374
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
IMNN-001
Biological
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combinatorial Therapy to Induce an HIV Remission

NCT04357821
View directory record Official record
Conditions
HIV/AIDS
Interventions
Combination Intervention
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 67 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 13, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

NCT06474676
View directory record Official record
Conditions
Metastatic Soft-tissue Sarcoma
Interventions
Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

NCT00004070
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
IL-12
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 13, 2026, 5:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT03167437
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vorinostat, Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 13, 2026, 5:28 PM EDT
Terminated Not applicable Interventional

Treatment of Chronic Cryptosporidiosis in AIDS Patients

NCT00001128
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Interleukin-12, Paromomycin sulfate, Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

NCT00323206
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IL-12p DNA, Intratumoral Electroporation
Biological · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 13, 2026, 5:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Pembrolizumab and M032 (NSC 733972)

NCT05084430
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
Interventions
M032, Pembrolizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 13, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional Results available

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

NCT02994953
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Avelumab, M9241, Avelumab (Once weekly), M9241 (MTD), Avelumab (Expansion cohort)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
San Diego, California • Santa Rosa, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy

NCT00005779
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12, HIV-1 C4-V3 Polyvalent Peptide Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 13, 2026, 5:28 PM EDT
Completed Phase 2 Interventional

Interleukin-12 in Treating Patients With Multiple Myeloma

NCT00003149
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
10
States / cities
Indianapolis, Indiana • Des Moines, Iowa • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 13, 2026, 5:28 PM EDT